ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
How to be different in in vivo Car-T
After Astra's EsoBiotec takeover the battle for uniqueness begins.
SGO 2025 – Genmab’s advantage looks Profound
While Sutro shows why it’s shelved luvelta-T.
ITM hopes to Compete against Lutathera
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
